Anne E OShea
Overview
Explore the profile of Anne E OShea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
OShea A, Valdera F, Ensley D, Smolinsky T, Cindass J, Kemp Bohan P, et al.
Clin Immunol
. 2022 Aug;
245:109095.
PMID: 35973640
Rapamycin inhibits the mechanistic (formally mammalian) target of rapamycin (mTOR), an evolutionarily conserved intracellular kinase that influences activation of growth signaling pathways and immune responses to malignancy. Rapamycin has been...
12.
OShea A, Carpenter E, Nelson D, Vreeland T
Ann Surg Oncol
. 2022 May;
29(9):6029-6030.
PMID: 35583695
No abstract available.
13.
OShea A, Kemp Bohan P, Carpenter E, McCarthy P, Adams A, Chick R, et al.
Ann Surg Oncol
. 2022 May;
29(9):6015-6028.
PMID: 35583691
Background: Neoadjuvant chemotherapy (NAC) or chemoradiation (NAC+XRT) is incorporated into the treatment of localized pancreatic adenocarcinoma (PDAC), often with the goal of downstaging before resection. However, the effect of downstaging...
14.
OShea A, Lee C, Kauvar D
Ann Vasc Surg
. 2022 Apr;
87:147-154.
PMID: 35460859
Background: The implications of major venous injury to the lower extremity are not well established. We aimed to determine the significance of concomitant and isolated femoropopliteal venous injury and assess...
15.
OShea A, Clifton G, Peoples G
Oncotarget
. 2021 Nov;
12(23):2318-2319.
PMID: 34786184
No abstract available.
16.
Adams A, Chick R, Vreeland T, Clifton G, Hale D, McCarthy P, et al.
Melanoma Res
. 2021 Jul;
31(4):378-388.
PMID: 34193804
Immunotherapy has revolutionized the treatment of melanoma, yet survival remains poor for patients with metastatic disease. The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine has been shown to be...
17.
McCarthy P, Rendo M, Uy M, Adams A, OShea A, Nelson D, et al.
Onco Targets Ther
. 2021 Jun;
14:3537-3544.
PMID: 34103944
Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant...
18.
Kemp Bohan P, OShea A, Ellis O, Chick R, Clem A, Kirby D, et al.
Ann Surg Oncol
. 2021 Feb;
28(6):2960-2972.
PMID: 33566248
Introduction: Lymphadenectomy (LND) is recommended following surgical resection of ≥ T1b gallbladder cancer (GBC). However, frequency and stage-specific survival benefits of LND remain unclear. Patients And Methods: The National Cancer...
19.
Kemp Bohan P, Chick R, OShea A, Vreeland T, Hickerson A, Cindass J, et al.
Cancer Prev Res (Phila)
. 2021 Jan;
14(5):551-562.
PMID: 33514567
No approved medical therapies prevent progression of low-grade prostate cancer. Rapamycin inhibits cell proliferation and augments immune responses, producing an antitumor effect. Encapsulated rapamycin (eRapa) incorporates rapamycin into a pH-sensitive...
20.
Kemp Bohan P, OShea A, Lee A, Chick R, Newhook T, Tran Cao H, et al.
Surg Oncol
. 2021 Jan;
36:138-146.
PMID: 33418464
Background And Objectives: Routine lymphadenectomy (LND) for resectable hepatocellular carcinoma (HCC) remains controversial. We evaluated national LND trends to identify pre-operative factors associated with node-positive disease to determine which patients...